Randomized Controlled Trial: High-Dose vs. Low-Dose Statin in Stable Coronary Artery Disease
10 May, 2018 | 17:55h | UTCWith a median follow-up of 3.9 years, high-dose as compared with low-dose pitavastatin significantly reduced the risk of the primary end point (4.3% vs 5.4%; NNT = 90), a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, or unstable angina requiring emergency hospitalization.